- Conditions
- Breast Cancer
- Interventions
- Gedatolisib, Faslodex, Palbociclib, Zoladex
- Drug
- Lead sponsor
- Hoffman Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • The Bronx, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 879
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Interventions
- PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more
- Conditions
- Vulvovaginal Atrophy
- Interventions
- WC3011 Estradiol Vaginal Cream
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 64
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
- Conditions
- Hot Flushes, Menopause, Postmenopause
- Interventions
- Esterified Estrogens (EE) and Methyltestosterone (MT)
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 1,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 88
- States / cities
- Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Belzutifan, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more
- Conditions
- Obesity, Glucose Homeostasis, Postmenopausal Symptoms
- Interventions
- Bazedoxifene/Conjugated Estrogens (BZA/CE), Placebo Oral Tablet
- Drug
- Lead sponsor
- Tulane University Health Sciences Center
- Other
- Eligibility
- 50 Years to 60 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 18 more
- Conditions
- Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
- Interventions
- Palbociclib, Bosutinib, Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Postmenopause, Aging
- Interventions
- Estradiol infusion, Progesterone infusion
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years to 80 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- 3 mg DRSP/20 μg EE
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 16 Years to 35 Years · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Congenital Central Hypoventilation Syndrome
- Interventions
- Desogestrel
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 16 Years to 50 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Overweight, Obesity
- Interventions
- NNC0662-0419, Oral contraceptive, Acetaminophen
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Mammographic Density, Abnormal Mammogram
- Interventions
- CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 42 Years to 58 Years · Female only
- Enrollment
- 517 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- THALASSEMIA MAJOR
- Interventions
- Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
- Other
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, MLN9708
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Risk Reduction, Breast Cancer
- Interventions
- Bazedoxifene and Conjugated Estrogens
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 45 Years to 64 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • San Francisco, California • Chicago, Illinois + 3 more
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Interventions
- therapeutic estradiol, deslorelin, therapeutic testosterone, therapeutic conventional surgery, active surveillance, quality-of-life assessment, laboratory biomarker analysis
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years to 48 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced HR+/HER2- Breast Cancer
- Interventions
- IEV407, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Dallas, Texas
- Conditions
- Exercise-related Amenorrhea
- Interventions
- Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator
- Drug · Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 21 Years · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sciatic Nerve Injury
- Interventions
- Autologous Human Schwann cells
- Biological
- Lead sponsor
- W. Dalton Dietrich
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Contraception
- Interventions
- Norethindrone acetate/ethinyl estradiol
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1,683 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more
- Conditions
- Female Breast Carcinoma, Female Ductal Carcinoma In Situ
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- Atossa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New York, New York • The Bronx, New York
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Interventions
- Hormone biomarker analysis, QoL Questionnaires
- Diagnostic Test · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more